British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...

“Appropriate people at higher risk should be vaccinated, and this will not only benefit the vaccinated person, but will ...

The FDA has accepted for review the sBLA to expand the indication of Arexvy (RSV vaccine, adjuvanted) to adults aged 18 to 49 years who are at increased risk.

Researchers from Cornell and Northwestern universities have developed a rapid, cell-free method for building nanoparticle ...